Format
Items per page
Sort by

Send to:

Choose Destination

Results: 14

1.

Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry.

Vermeer M, Kievit W, Kuper HH, Braakman-Jansen LM, Bernelot Moens HJ, Zijlstra TR, den Broeder AA, van Riel PL, Fransen J, van de Laar MA.

BMC Musculoskelet Disord. 2013 Dec 13;14:350. doi: 10.1186/1471-2474-14-350.

2.

Sustained beneficial effects of a protocolized treat-to-target strategy in very early rheumatoid arthritis: three-year results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort.

Vermeer M, Kuper HH, Moens HJ, Drossaers-Bakker KW, van der Bijl AE, van Riel PL, van de Laar MA.

Arthritis Care Res (Hoboken). 2013 Aug;65(8):1219-26. doi: 10.1002/acr.21984.

PMID:
23436821
3.

Adherence to a treat-to-target strategy in early rheumatoid arthritis: results of the DREAM remission induction cohort.

Vermeer M, Kuper HH, Bernelot Moens HJ, Hoekstra M, Posthumus MD, van Riel PL, van de Laar MA.

Arthritis Res Ther. 2012 Nov 23;14(6):R254. doi: 10.1186/ar4099.

4.

The provisional ACR/EULAR definition of remission in RA: a comment on the patient global assessment criterion.

Vermeer M, Kuper HH, van der Bijl AE, Baan H, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.

Rheumatology (Oxford). 2012 Jun;51(6):1076-80. doi: 10.1093/rheumatology/ker425. Epub 2012 Feb 1.

5.

A tight control treatment strategy aiming for remission in early rheumatoid arthritis is more effective than usual care treatment in daily clinical practice: a study of two cohorts in the Dutch Rheumatoid Arthritis Monitoring registry.

Schipper LG, Vermeer M, Kuper HH, Hoekstra MO, Haagsma CJ, Den Broeder AA, van Riel P, Fransen J, van de Laar MA.

Ann Rheum Dis. 2012 Jun;71(6):845-50. doi: 10.1136/annrheumdis-2011-200274. Epub 2011 Dec 30.

PMID:
22210852
6.

Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study.

Vermeer M, Kuper HH, Hoekstra M, Haagsma CJ, Posthumus MD, Brus HL, van Riel PL, van de Laar MA.

Arthritis Rheum. 2011 Oct;63(10):2865-72. doi: 10.1002/art.30494.

7.

Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice.

Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, Brus HL, van de Laar MA, van Riel PL.

Arthritis Care Res (Hoboken). 2010 Sep;62(9):1335-41. doi: 10.1002/acr.20211.

PMID:
20506128
8.

Evaluating guidelines on continuation of anti-tumour necrosis factor treatment after 3 months: clinical effectiveness and costs of observed care and different alternative strategies.

Kievit W, Fransen J, Adang EM, Kuper HH, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, van de Laar MA, Van Riel PC.

Ann Rheum Dis. 2009 Jun;68(6):844-9. doi: 10.1136/ard.2008.094359. Epub 2008 Jul 14.

PMID:
18625616
9.

The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data.

Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, De Gendt CM, De Rooij DJ, Brus HL, Van Oijen PC, Van Riel PC.

Ann Rheum Dis. 2008 Sep;67(9):1229-34. doi: 10.1136/ard.2007.083675. Epub 2008 Jan 3.

PMID:
18174220
10.

The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice.

Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, De Gendt CM, Ronday KH, Jansen TL, van Oijen PC, Brus HL, Adang EM, van Riel PL.

Ann Rheum Dis. 2007 Nov;66(11):1473-8. Epub 2007 Apr 10. Review.

11.

Socio-economic consequences of rheumatoid arthritis in the first years of the disease.

Albers JM, Kuper HH, van Riel PL, Prevoo ML, van 't Hof MA, van Gestel AM, Severens JL.

Rheumatology (Oxford). 1999 May;38(5):423-30.

12.

Radiographic damage in large joints in early rheumatoid arthritis: relationship with radiographic damage in hands and feet, disease activity, and physical disability.

Kuper HH, van Leeuwen MA, van Riel PL, Prevoo ML, Houtman PM, Lolkema WF, van Rijswijk MH.

Br J Rheumatol. 1997 Aug;36(8):855-60.

13.

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL.

Arthritis Rheum. 1995 Jan;38(1):44-8.

PMID:
7818570
14.

Validity and reliability of joint indices. A longitudinal study in patients with recent onset rheumatoid arthritis.

Prevoo ML, van Riel PL, van 't Hof MA, van Rijswijk MH, van Leeuwen MA, Kuper HH, van de Putte LB.

Br J Rheumatol. 1993 Jul;32(7):589-94.

PMID:
8339131
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk